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Background and Purpose: The beneficial effects of bone marrow mononuclear cell (BM-
MNC) transplantation in preclinical experimental stroke have been reliably demonstrated. 
However, only overall modest effects in clinical trials were observed. We have investigated and 
report a cause of the discrepancy between the pre-clinical and clinical studies. 
Methods: To investigate the possible cause of low efficacy of BM-MNC transplantation in 
experimental stroke, we have focused on blood clot formation which is not uncommon in 
human bone marrow aspirates. In order to evaluate the effects of clot-derived contaminants in 
transplanted BM-MNC on stroke outcome, a murine stroke model was employed.  
Results: We show that BM-MNC separated by an automatic cell isolator (Sepax2), which does 
not have the ability to remove clots, did not attenuate brain atrophy after stroke. In contrast, 
manually isolated, clot-free BM-MNC exerted therapeutic effects. Clot-derived contaminants 
were also transplanted intravenously to post-stroke mice. We found that the transplanted 
contaminants were trapped at the peri-stroke area, which were associated with 
microglial/macrophage activation. 
Conclusion: Clot-derived contaminants in transplanted BM-MNC nullify therapeutic effects 
in experimental stroke. This may explain neutral results in clinical trials, especially in those 
using automated stem cell separators that lack the ability to remove clot-derived contaminants. 
  





The beneficial effects of bone marrow mononuclear cells (BM-MNC) transplantation in 
experimental stroke model had been shown in a number of experiments.1,2 BM-MNC contain 
various cells, including lymphoid, myeloid, erythroid, and stem cell populations. Although 
individual BM-MNC populations were shown to exert different effects on stroke recovery3, 
multiple therapeutic BM-MNC effects have also been proposed, including neuroprotection by 
monocytes within the myeloid fraction3,4, and induction of neurogenesis by CD34+ 
hematopoietic stem/progenitor cells (HSC)5 representing about 1.5 % of BM-MNC.6 Clinical 
trials employing BM-MNC transplantation for stroke have been conducted and both positive6 
and neutral7,8 results have been reported. Mixed results were also reported after BM-MNC 
transplantation in myocardial infarction.9 Meta-analysis of clinical trials have revealed the 
safety and feasibility of the approach but further well-designed large-scale, randomized and 
controlled trials are required to investigate their efficacy.10 The discrepancy between the 
positive effects in preclinical studies and the overall modest effects in clinical trials led us to 
investigate the role of an inhibitor which suppresses therapeutic effects of BM-MNC in clinical 
trial. 
Human bone marrow aspirate is prone to clot formation due to its high viscosity11 and the 
presence of lipids, connective tissue, and megakaryocytes.12 Damaged cells and substances 
from these can activate microglia/macrophages, causing proinflammatory responses13 which 




can have detrimental effects on post-stroke recovery.14 Based on these findings, we have 
investigated the effect of clot-derived contaminants in BM-MNC transplantation after cerebral 
ischemia in experimental stroke model. 
 
Methods 
This article adheres to the American Heart Association Journals Implementation of the 
Transparency and Openness Promotion Guidelines. The data supporting the findings of this 
study are available from the corresponding author on reasonable request. 
All animal experiments were approved by the Animal Care and Use Committee of Foundation 
for Biomedical Research and Innovation and complies with the Guide for the Care and Use of 
Animals published by the Japanese Ministry of Education, Culture, Sports, Science and 
Technology.  
 
Murine stroke model 
Seven weeks old male severe combined immunodeficiency CB-17/lcr-scid/scidJcl (SCID) 
mice (Oriental Yeast, Tokyo, Japan) were used as recipients for human BM-MNC. Wild type 7 
weeks old male CB-17/lcr-+/+Jcl mice (Oriental Yeast) received litter mate murine BM-MNC. 
Experimental design is shown in Figure 1. Permanent middle cerebral artery occlusion 
(MCAO) was induced as described previously.5,15 Briefly, the distal MCA portion was ligated 




and disconnected using bipolar forceps under 3 % isoflurane inhalation anesthesia. During 
surgery, rectal temperature was monitored and maintained at 37.0±0.2°C using a feedback-
regulated heating pad. Cerebral blood flow (CBF) in the MCA territory was measured with 2D 
laser blood flow imaging (Muromachi, Tokyo, Japan). All mice showed a ~75 % decreased 
CBF immediately after MCA occlusion as well as 48 hr after ligation. 
 
Preparation of human BM-MNC 
Human bone marrow (BM) aspirate was purchased from LONZA (Basel, Switzerland) and 
BM-MNC were purified manually or by an automatic cell separator (Sepax2; GE Healthcare, 
Buckinghamshire, UK) at day 4 after harvest. All materials and reagents, including human BM 
aspirate and density centrifugation medium (Ficoll-Paque Premium, GE) were identical 
between the procedures. For manual separation, BM was diluted 4-fold with saline (Otsuka 
Pharmaceutical, Tokyo, Japan), layered on Ficoll-Paque Premium, and centrifuged at 400g for 
40 min. Cells in buffy coat, whilst carefully avoiding any clot contamination, were isolated 
manually and washed 3 times with saline. Clots in buffy coat were also collected and washed 
3 times with saline and digested using 23G needle/syringe. For automated purification, 50 ml 
of human BM was loaded to Sepax2, and BM-MNC were isolated with Ficoll-Paque Premium 
using the automatic cell separation mode according to manufacturer’s instruction. The number 
of white blood cells (WBC), RBC and platelets/cell debris in randomly selected 0.01 mm2 were 




counted a by blinded investigator (N=6, in each samples). 
 
Murine BM-MNC preparation 
Murine BM was obtained from tibias and femurs of adult male CB-17 mice, resuspended by 
saline, layered on Ficoll-Paque Premium, and centrifuged at 400g for 40 min. BM-MNC in 
buffy coat were isolated manually. For clot formation, thrombin (50 U final concentration, 
Mochida, Tokyo, Japan), Alexa Fluor 647-labelled fibrinogen (0.6 mg/ml final concentration, 
Molecular Probes, OR, USA), and CaCl2 (5 mM in final concentration) were added to BM-
MNC and incubated for 30 s at room temperature. For experiment using labelled cells, BM-
MNC were stained with green fluorescent dye (Cell tracker Green CMFDA, 5 µM final 
concentration, Molecular Probes, OR, USA) before clot formation. Clots were washed twice 
with PBS, digested using 23G needle/syringe, and filtered through cell strainers (pore size 35 
µm, BD Bioscience, MA, USA) before injection. 
 
Cell transplantation 
In each experiment, 1x105 BM-MNC in 100 µl PBS or vehicle was injected intravenously 48 
h after stroke induction. For morphological and immunohistochemical analysis, mice were 
anesthetized with sodium pentobarbital, and perfused transcardially with saline followed by 
4% paraformaldehyde. Whole brain images were captured by a digital camera system 




(Olympus, Tokyo, Japan), and the area of each hemisphere was measured with ImageJ 
(National Institutes of Health, Bethesda, MD, USA) by blinded investigators. The value of 
[(right hemisphere) – (left hemisphere)]/(right hemisphere) x 100 was defined as brain atrophy 
in area (%). 
 
Immunohistochemistry 
Coronal sections (20 µm) were prepared using a vibratome (Leica,Wetzlar, Germany) and 
immunostained with primary antibodies against F4/80 (dilution 1:50; Serotec, Raleigh, NC, 
USA), CD11b (dilution 1:250; Serotec, Raleigh, NC, USA), or CD31 (dilution 1:50; BD 
Pharmingen, San Jose, CA, USA). Anti-CD11b, and anti-CD31 were visualized by the 3,3'-
diaminobenzidine method, and counterstained with Mayer’s hematoxylin solution (Wako, 
Osaka, Japan). The number of CD11b positive cells in a randomly selected 0.1 mm2 region of 
interest in the peri-stroke area was quantified by a blinded investigator. To assess the deposition 
of clot-derived cell debris and fibrinogen at microglia/macrophages, Alexa555-coupled 
antibodies (dilution 1:500; Thermo Fisher Scientific, Waltham, MA, USA) were used as the 
secondary antibody to anti-F4/80. 
 
Cell analysis by fluorescence-activated cell sorting (FACS) 
Anti-CD45 (PE, BD Bioscience) and Ter119 (PerCP-Cy5.5, BD Bioscience) antibodies were 




used to identify WBC and RBC, respectively. Cells were incubated with antibodies for 15 min 
at 4°C and washed with PBS containing 1 % of fetal bovine serum (Thermo Fisher Scientific). 
A FACS Calibur (BD Bioscience) was used for cell analysis. CD45-positive cells with reduced 
FSC signal (outside of normal WBC gate) were considered as denatured WBC, and Ter119-
positive cells with reduced FSC signal were counted as denatured RBC. 
 
Data analysis 
Statistical comparisons among groups were conducted using one-way analysis of variance 
(ANOVA) followed by post-hoc analysis using Dunnett's test. In all experiments, the mean ± 
SD is reported. 
 
Results 
Human BM-MNC isolated by Sepax2 did not attenuate post-stroke brain atrophy in 
murine stroke model 
Sepax2 is a fit-for-purpose device for isolating BM-MNC by gravity centrifugation and is 
broadly used clinically for allogenic hematopoietic stem cell transplantation.16 However, 
Sepax2 does not have the ability to remove clots from the buffy coat. We compared the effect 
of Sepax2 and manually purified BM-MNC on experimental stroke outcomes. 
Figure 2A shows BM-MNC and clots at the buffy coat after gravity centrifugation as applied 




during manual cell isolation. It should be noted that most RBC precipitate at the bottom, but 
small clots remain within the buffy coat after centrifugation. It was carefully avoided to aspirate 
these clots during manual processing. Figure 2B shows manually isolated BM-MNC, Sepax2-
isolated BM-MNC, and clots at the buffy coat derived cells, respectively. In contrast to manual 
separation, a number of RBC and platelets/cell debris were observed in Sepax2-isolated BM-
MNC. RBC and platelets/cell debris were also observed in BM-MNC suspension obtained from 
clots at the buffy coat. Figure 2C shows the ratio of contaminated RBC and platelet/cell debris 
versus WBC in each sample, revealing significantly higher contamination in Sepax2-isolated 
BM-MNC compared to manually isolated BM-MNC. 
We had previously demonstrated that CD34+ HSC transplantation after experimental stroke 
induces regenerative process and attenuates of post-stroke brain atrophy.5 Here, Sepax2-
isolated, clot-derived or manually isolated BM-MNC were intravenously injected into stroke 
mice 48 h after stroke induction. At day 30 after cell transplantation, whole brain images were 
captured to investigate the effect of cell transplantation (Figure 3A). The attenuation of the 
atrophy was evaluated and we found that mice receiving manually separated BM-MNC showed 
attenuated post-stroke brain atrophy compared to PBS controls (Figure 3B). In contrast, mice 
which received BM-MNC isolated by Sepax2 showed no attenuation of brain atrophy.  
 
Transplantation of Sepax2-isolated BM-MNC preserves cerebral microvasculature but is 




associated with increased CD11b-positive cell counts 
We previously showed that BM-MNC transplantation after stroke preserves the microvascular 
structure followed by attenuation of brain atrophy and functional recovery.17,18 To investigate 
the cause of the neutral results seen after Sepax2-isolated BM-MNC transplantation in clinical 
trials, brain tissue was harvested 24 h after cell transplantation to investigate effect on the 
microvasculature (Figure 4A). Compared with PBS-injected control mice, mice receiving 
manually isolated or Sepax2-isolated BM-MNC showed preservation of microvascular 
structures in the infarct area (Figure 4B).  
We also showed that enhanced inflammatory responses within the peri-stroke area 
detrimentally affect stroke outcome.18 To investigate the effect of cell transplantation on 
microglia/macrophage activation, brain sections were investigated using anti-CD11b 
antibodies at 24 h after cell transplantation. Compared with mice that received PBS or manually 
isolated BM-MNC, mice receiving Sepax2-isolated BM-MNC had higher numbers of CD11b-
positive cells (microglia/macrophages) in peri-stroke areas (Figure 4C, D). These data indicate 
that cells isolated by Sepax2 can generally preserve microvasculature structures at infarct area 
but enhance inflammatory cell presence in peri-stroke areas.   
 
Injection of clot-derived cells/debris enhances microglia/macrophage numbers in peri-
stroke areas 




To investigate the effect of clot-derived cells/debris on CD11b-positive microglia/macrophage 
numbers, clots were formed with mice BM-MNC, fibrinogen, thrombin and Ca2+ ions. Figure 
I (SUPPLEMENTAL INFORMATION) shows the results of FACS analysis before (Figure I, 
A-E) and after clot formation (Figure I, F-J). It should be noted that RBC were contaminated 
in isolated mice BM-MNC. The FSC level of CD45-positive WBC and Ter119-positive RBC 
(Figure I, I-J) was decreased after clot formation (Figure I, D and E, respectively). The 
percentage of degenerated WBC (vs all WBC-positive cells) was 3.4 %/ 48.4 % before/after 
clot formation. Similarly, the percentage of degenerated RBC (versus all WBC-positive cells) 
was 0.5 %/75.3 % before/after clot formation. 
To confirm the hypothesis that clot-derived cells/debris interact with microglia/macrophages 
in peri-stroke areas, mice BM-MNC with contaminated RBC were labelled with CMFDA 
before clot formation. The BM-MNC before or after clot formation were intravenously 
transplanted 48h after stroke induction, and animals were sacrificed 20 minutes later. No 
transcardial perfusion with saline/paraformaldehyde was performed in this experiment to 
identify the localization of transplanted cells/debris. No microglia/macrophage was CMFDA- 
or Alexa 647-positive in mice that received cells before clot formation, and CMFDA and Alexa 
647 signals were exclusively located inside the microvasculature (Figure 5A). In contrast, 
CMFDA and Alexa 647-positive microglia/macrophages were observed in mice that received 
clot-derived cells/debris (Figure 5B). These results indicate that clot-derived contaminants 




interact microglia/macrophage in peri-stroke areas. 
 
Removal of clot-derived denatured cells/debris restores BM-MNC the therapeutic effects  
Compared to other density centrifugation medium, the advantage of Ficoll-paque had been 
suggested in comparison of clinical trials using BM-MNC transplantation for cardiac 
ischemia.19 Ficoll-paque consists of Ficoll PM400 and sodium diatrizoate, and Ficoll PM400 
is a highly branched hydrophilic sugar polymer20-22 that can interact with denatured cells. 
Figure II (SUPPLEMENTAL INFORMATION) shows the FACS analysis of BM (not cells 
obtained from buffy coat, but freshly isolated cells from tibias and femurs) washed with PBS 
or Ficoll-PM400. The percentage of denatured WBC (vs all WBC-positive cell) was 10.0 % 
versus 5.9 % in cells washed with PBS and Ficoll-PM400, respectively. Similarly, the 
percentage of denatured RBC (versus all WBC-positive cell) was 3.3% versus 2.5% in cells 
washed with PBS (SUPPLEMENTAL INFORMATION, Figure II A-E) and Ficoll-PM400 
(SUPPLEMENTAL INFORMATION, Figure II F-I), respectively. Cells were transplanted 48 
h after stroke induction, and effects were investigated at day 30 after cell transplantation. 
Compared with PBS injected control, mice that received cells washed with Ficoll-PM400 
showed significant attenuation of post-stroke brain atrophy at day 30, though cells washed with 
PBS failed to induce this effect (SUPPLEMENTAL INFORMATION, Figure II K). These 
results supported our hypothesis that removal of denatured WBC and RBC in transplanted BM-




MNC is essential for the cells’ therapeutic effect after stroke. 
 
Discussion 
We report herein that clot-derived contaminants in transplanted BM-MNC impair the 
therapeutic effect, presumably be creasing proinflammatory microglia/macrophage load in 
peri-stroke areas. Our data might contribute to the explanation of neutral and negative results 
of clinical trials using autologous BM-MNC transplantation for ischemic diseases, especially 
transplantation of cells isolated by automatic cell separators such as the Sepax2. 
BM-MNC therapy has been initiated for limb ischemia and in ischemic wound healing with 
angiographic findings and physiological parameters being reported.23 However, non-
responders to cell therapy exist24,25 and both positive26,27 and neutral/negative28,29 results have 
been reported in double blinded, placebo-controlled studies using autologous BM-MNC 
transplantation for myocardial infarction. The reasons of the contradictory results are currently 
unclear. BM aspiration fluid contains various cells/substances, including connective tissue, 
bone fragments, and lipids. These substances trigger the coagulation cascade and clot formation 
is observed to a greater or lesser extent in many cases.30 Our results show that transplantation 
of clot-derived contaminants augments microglia/macrophage numbers in peri-stroke areas and 
impairs the effect of cellular therapy, although transplanted BM-MNC still preserved the 
microvasculature in the lesion area. Our results could help to explain neutral and negative 




results in clinical trial using Sepax2-isolated BM-MNC transplantation in myocardial 
ischemia,31 which are in contrast to the positive results after using manually isolated BM-
MNC.32 
Intra-arterial cell delivery is gaining momentum based on technical improvements and 
widespread application of thrombectomy. Intra-arterial cell transplantation has a significant 
advantage of delivering more cells to where they are exactly needed, avoiding peripheral 
filtering effects, for instance in lungs. However, the therapeutic effects of intra-arterial BM-
MNC had been shown to be not superior to intravenous transplantation in experimental 
stroke.18,33 Moreover, intra-arterial transplantation would delivers higher amounts of clot-
derived contaminants directly to the brain if cells are not optimally prepared, potentially 
offsetting additional therapeutic benefits gained by the approach. This could explain the reason 
why intra-arterial BM-MNC is not superior to intravenous transplantation and indicated the 
quality of cell preparation may particularly matter for the selection of delivery route.  
Positive effects of thrombectomy for stroke patients are increasingly reported. Significant 
benefits of clot removal up to 24 h after stroke onset was shown34 and the effect of clot removal 
beyond 24 h was also suggested.35 Our current results regarding enhanced presence of 
proinflammatory microglia/macrophages by clot derived substances indicates that 
thrombectomy would be not only important for blood flow restoration, but would also mitigate 
clot-borne neuroinflammation.  




Microglia play an important role in post-stroke pathophysiology, but discrimination of 
microglia and macrophages is challenging.36 The origin of activated microglia/macrophage by 
clot-derived contaminants in peri-stroke areas can be local microglia, clot-derived cells, or 
circulating macrophages. In this study, many F4/80-positive microglia/macrophages in peri-
stroke were CMFDA-/Alexa 647-positive in mice that received clot-derived cells/debris. Since 
tissue was obtained as early as 20 minutes after stroke induction, we speculate that the origin 
of activated microglia/macrophage within peri-stroke areas is not an enhanced ingress of 
activated macrophages, but enhanced activation of local microglia.  
In conclusion, our results indicate that the exclusion of clot-derived contaminants in 
transplanted bone marrow mononuclear cells is a critical factors for BMM-MNC therapy and 
can explain neutral or negative results in clinical trials using automatic cell separators which 
do not have the ability to remove clots from the buffy coat. Our data also emphasizes the 
importance of the clarification of the therapeutic mechanisms for the improvement of 
therapeutic effect of cell therapy. 
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Figure 1. Design of in vivo experiments 
Schematic illustration of in vivo experimental design. 
 
Figure 2. Isolated human BM-MNC  
(A) In the process of manual cell isolation, clots (arrows) were observed at the buffy coat after 
gravity centrifugation. (B, C) Compared to manually isolated BM-MNC, Sepax2 isolated BM-
MNC and cells in clots contain significantly much more RBC and platelets/cell debris. Red and 
black arrow heads indicate RBC and platelets/cell debris, respectively. Scale bars, 1 cm (A) 
and 10 µm (B). *p<0.01 vs manual, #p<0.01 vs Sepax2, N=6 views in each group (C).  
 
Figure 3. Sepax2 isolated BM-MNC did not show therapeutic effect after stroke 
(A) Brain images 30 days after stroke induction. (B) The areas of left and right hemisphere 
(HS) were measured. Compared to control, significant attenuation of brain atrophy was 
observed only in mice that received manually processed BM-MNC. Scale bar, 2.5 mm (A). 
*p<0.01, N=9 in each group (B). 
 
Figure 4. Activation of microglia/macrophage after Sepax2 isolated cell transplantation 
(A) Schematic illustration of lesion and peri-stroke area. (B) Mice that received PBS showed 




microvascular narrowing, indicating vessel breakdown in the lesion area. In contrast, 
microvasculature was preserved in mice that received manually or Sepax2-isolated BM-MNC. 
(C, D) Mice that received PBS and manually isolated cells showed mild activation of CD11b-
positive microglia/macrophages in peri-stroke areas. In contrast, transplantation of Sepax2-
isolated BM-MNC was associated with higher microglia/macrophage numbers. Scale bars, 100 
µm (B, C; upper panel), 50 µm (B, C; lower panel). *p<0.01 versus manual, N=6 in each group 
(D).  
 
Figure 5. Injection of clot-derived cells/debris augments microglia/macrophage activation 
at peri-stroke area 
(A) No F4/80-positive microglia/macrophages with incorporated CMFDA or Alexa 647 were 
observed in mice that received cells before clot formation. (B) In contrast, 
microglia/macrophages incorporating CMFDA and Alexa 647 were observed when 
transplanting clot-derived, labelled cells/debris. Upper and lower panels show lower and higher 
magnification, respectively. Scale bars, 20 µm (A; upper panel), 10 µm (A; lower panel). 
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Figure. 5 
 
 
